Compare United States Copper Index Fund (CPER) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Incyte Corporation — how do they compare? United States Copper Index Fund trades at $40.1 (market cap $708.28M), while Incyte Corporation trades at $112.8 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 32.3× United States Copper Index Fund's market cap, and United States Copper Index Fund is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Incyte Corporation for 33 Days on average.
| CPER | INCY | |
|---|---|---|
Market Cap | $708.28M | $22.85B |
Volume | 339,046 | 1,927,029 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $129.93 |
52-Week Low | $30.27 | $83.80 |
Typical Hold Time | 48 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish momentum in moving averages but neutral oscillators, with key support at $39 and resistance at $40. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper prices have shown volatility with recent declines.
The outlook for CPER is mixed, with positive copper demand fundamentals balanced by near-term price volatility. Investment opportunities center on exposure to copper's role in AI and electrification trends, while risks include commodity price swings and potential supply chain disruptions. Wall Street sentiment appears cautiously optimistic given copper's strategic importance.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
